var data={"title":"Pantoprazole: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pantoprazole: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6721?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pantoprazole-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pantoprazole: Patient drug information&quot;</a> and <a href=\"topic.htm?path=pantoprazole-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Pantoprazole: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50836901\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Proton Pump Inhibitors Safety Alert</span>\n      <span class=\"collapsible-date\">December 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Health Canada has issued a safety alert regarding the rare risk of subacute cutaneous lupus erythematosus with the use of proton pump inhibitors (PPI). This alert was prompted following a published article that examined reports in the FDA Adverse Event Reporting System.</p>\n        <p style=\"text-indent:0em;\">Health Canada is working with manufacturers to update the safety information to include these findings in all PPI-containing products. More information may be found at https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/proton-pump-inhibitors-assessing-risk-type-skin-reaction.html.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206239\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Protonix</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206240\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Panto I.V.;</li>\n      <li>Pantoloc;</li>\n      <li>Tecta</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206284\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Proton Pump Inhibitor;</li>\n      <li>\n        Substituted Benzimidazole</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206244\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Erosive esophagitis associated with GERD: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Oral:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment: 40 mg once daily for up to 8 weeks; an additional 8 weeks may be used in patients who have not healed after an 8-week course. Lower doses (20 mg once daily) have been used successfully in mild GERD treatment (Dettmer 1998).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance of healing: 40 mg once daily; 20 mg once daily has been used successfully in maintenance of healing (Escourrou 1999). <b>Note:</b> Has not been studied beyond 12 months.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IV:</i> 40 mg once daily for 7 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pathological hypersecretory conditions, including Zollinger-Ellison syndrome:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Oral:</i> Initial: 40 mg twice daily; adjust dose based on patient needs; doses up to 240 mg daily have been administered</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IV:</i> 80 mg every 12 hours; adjust dose based on acid output measurements; 160 to 240 mg daily in divided doses has been used for a limited period (up to 7 days)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of rebleeding in peptic ulcer bleed (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IV:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Continuous infusion:</i> Loading dose of 80 mg, followed by 8 mg/hour infusion for 72 hours (Barkun 2010; Zargar 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Intermittent dosing:</i> Loading dose of 80 mg followed by either 40 mg every 12 hours for 72 hours (Hung 2007; Yamada 2012) <b>or</b> 40 mg every 6 hours for 72 hours (Hsu, 2009). May also administer 40 mg every 12 hours for 72 hours without a loading dose (Yuksel 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> After completion, continue therapy with a single daily-dose oral PPI for a duration dictated by the underlying etiology (Barkun 2010; Laine 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Oral:</i> 40 mg once daily for 2 to 4 weeks (treatment of duodenal ulcer) or 4 to 8 weeks (treatment of gastric ulcer) (Pantoloc Canadian product labeling)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Helicobacter pylori</i></b> <b>eradication (off-label use):</b> Oral: American College of Gastroenterology guidelines (Chey 2007; Chey 2017):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Clarithromycin triple regimen: </i>40 to 80 mg twice daily in combination with clarithromycin 500 mg twice daily and either amoxicillin 1 g twice daily or metronidazole 500 mg 3 times per day; continue regimen for 14 days. <b>Note:</b> Avoid use of clarithromycin triple therapy in patients with risk factors for macrolide resistance (eg, prior macrolide exposure, local clarithromycin resistance rates &ge;15%, eradication rates with clarithromycin-based regimens &le;85%) (ACG [Chey 2017]; Fallone 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Bismuth quadruple regimen:</i> 40 mg twice daily in combination with tetracycline 500 mg 4 times per day, metronidazole 250 mg 4 times per day or 500 mg 3 or 4 times per day, and either bismuth subcitrate 120 to 300 mg 4 times per day or bismuth subsalicylate 300 mg 4 times per day; continue regimen for 10 to 14 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Concomitant regimen: </i>40 mg twice daily in combination with amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and either metronidazole or tinidazole 500 mg twice daily; continue regimen for 10 to 14 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Sequential regimen: </i>40 mg twice daily plus amoxicillin 1 g twice daily for 5 to 7 days; then continue pantoprazole along with clarithromycin 500 mg twice daily, and either metronidazole or tinidazole 500 mg twice daily for 5 to 7 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hybrid regimen: </i>40 mg twice daily plus amoxicillin 1 g twice daily for 7 days; then continue pantoprazole and amoxicillin along with clarithromycin 500 mg twice daily, and either metronidazole or tinidazole 500 mg twice daily for 7 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Levofloxacin triple regimen:</i> 40 mg twice daily in combination with amoxicillin 1 g twice daily and levofloxacin 500 mg once daily; continue regimen for 10 to 14 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of NSAID-induced ulcers (off-label):</b> Oral: 20 to 40 mg once daily (Bianchi Prollo 2000; Lanza 2009; Regula 2006)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5707304\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=pantoprazole-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Pantoprazole: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Erosive esophagitis associated with GERD:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 1 to 5 years: Limited data available: 0.3, 0.6, or 1.2 mg/kg/day once daily for 8 weeks was used in a dose-finding study of 60 patients with histologic or erosive esophagitis. High-dose treatment (1.2 mg/kg/day) was administered as a fixed dose of either: 15 mg for children 1 year of age <b>or</b> 20 mg for children 2 to 5 years of age. Patients with erosive esophagitis (n=4) received either 0.6 or 1.2 mg/kg/day (Baker 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;5 years and Adolescents: <b>Note: </b> Consider a dose reduction in known CYP2C19 poor metabolizers.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;15 to &lt;40 kg: 20 mg once daily for up to 8 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;40 kg: 40 mg once daily for up to 8 weeks</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206245\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206246\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary; pantoprazole is not removed by hemodialysis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206247\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary; doses &gt;40 mg daily have not been evaluated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206211\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Packet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Protonix: 40 mg (1 ea, 30 ea) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Protonix: 40 mg (1 ea) [contains edetate disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 40 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Delayed Release, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Protonix: 20 mg, 40 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg, 40 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206195\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5950137\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-4em;margin-left:4em;\">Solution Reconstituted, Intravenous:</p>\n    <p style=\"text-indent:-4em;margin-left:6em;\">Panto IV: 40 mg [contains edetate disodium]</p>\n    <p style=\"text-indent:-4em;margin-left:4em;\">Tablet Enteric Coated, Oral, as sodium:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pantoloc 20 mg. 40 mg</p>\n    <p style=\"text-indent:-4em;margin-left:4em;\">Tablet Enteric Coated, Oral, as magnesium:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tecta: 40 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15386979\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Protonix granules for oral suspension, delayed release tablets: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020987s053,022020s015lbl.pdf#page=30&amp;token=kJAC80Ianm2acD5sas7t+xUL6O3x65z6TVWP3ixDX9RvDDYAmyV1SzXePzEeerxzxtn34tPBLYuGo2RX8QOoBuAeyzqmiWKkkWPKhL/F1ligpyEGuKypq9RO67ovj3q5&amp;TOPIC_ID=9474\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020987s053,022020s015lbl.pdf#page=30</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206213\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Flush IV line before and after administration with D5W, NS, or LR. In-line filter not required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>2-minute infusion:</i> The volume of reconstituted solution (4 mg/mL) may be administered intravenously over at least 2 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>15-minute infusion:</i> Infuse over ~15 minutes at a rate of ~7 mL/minute (3 mg/minute).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Continuous infusion:</i> May also be administered as a continuous infusion for the prevention of rebleeding with in peptic ulcer bleed (off-label use).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet: Should be swallowed whole, do not split, crush, or chew. May administer with or without food; concomitant administration of antacids does not affect absorption.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Delayed-release oral suspension: Should only be administered in apple juice or applesauce and taken ~30 minutes before a meal; do not chew or crush granules. Do not administer with any other liquid (eg, water) or foods.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral administration in <b>applesauce</b>: Sprinkle intact granules on 1 teaspoon of applesauce and swallow within 10 minutes of preparation.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral administration in <b>apple juice</b>: Empty intact granules into 5 mL of apple juice, stir for 5 seconds (granules will not dissolve), and swallow immediately after preparation. Rinse container once or twice with apple juice and swallow immediately.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Nasogastric tube administration: Separate the plunger from the barrel of a 60 mL catheter tip syringe and connect to a &ge;16 French nasogastric tube. Holding the syringe attached to the tubing as high as possible, empty the contents of the packet into barrel of the syringe, add 10 mL of apple juice and gently tap/shake the barrel of the syringe to help empty the syringe. Add an additional 10 mL of apple juice and gently tap/shake the barrel to help rinse. Repeat rinse at least twice with 10 mL aliquots of apple juice. No granules should remain in the syringe.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14473039\" class=\"block uica drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 80 mg in 100 mL (concentration: 0.8 mg/mL) of D5W or NS</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206212\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Oral:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Erosive esophagitis associated with gastroesophageal reflux disease:</b> Short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis in adults and pediatric patients 5 years and older.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Maintenance of healing of erosive esophagitis:</b> Maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with gastroesophageal reflux disease (GERD).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pathological hypersecretory conditions, including Zollinger-Ellison syndrome: </b>Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>IV:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gastroesophageal reflux disease associated with a history of erosive esophagitis:</b> Short-term treatment (7 to 10 days) of adult patients with gastroesophageal reflux disease (GERD) and a history of erosive esophagitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pathological hypersecretory conditions, including Zollinger-Ellison:</b> Treatment of adult patients with pathological hypersecretory conditions, including Zollinger-Ellison syndrome.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25470196\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Helicobacter pylori eradication; Prevention of NSAID-induced ulcers; Prevention of rebleeding in peptic ulcer bleed; Stress ulcer prophylaxis in critically ill patients</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206294\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pantoprazole may be confused with ARIPiprazole</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Protonix may be confused with Lotronex, Lovenox, protamine</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Vials containing Protonix IV for injection are not recommended for use with spiked IV system adaptors. Nurses and pharmacists have reported breakage of the glass vials during attempts to connect spiked IV system adaptors, which may potentially result in injury to healthcare professionals.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Proton pump inhibitors are identified in the Beers Criteria as potentially inappropriate medications to be avoided (as scheduled use for more than 8 weeks) in patients 65 years and older due to its risk of <i>C. difficile</i> infection and bone loss/fractures. Use more than 8 weeks should be avoided unless given for high-risk patients (eg, oral corticosteroid or chronic NSAID use), patients with erosive esophagitis, Barrett's esophagitis, a pathological hypersecretory condition, or if the patient has demonstrated a need for maintenance therapy (eg, failure of drug discontinuation trial or failure of H<sup>2</sup> blockers) (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Protonix [US] may be confused with Pretanix brand name for indapamide [Hungary]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Protonix: Brand name for pantoprazole [US] but also the brand name for omeprazole [Phillipines]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206202\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Central nervous system: Headache (adults 12%; children &gt;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Facial edema (&le;4%), edema (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (&le;4%), vertigo (&le;4%), depression (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (adults &le;2%; children &gt;4%), urticaria (&le;4%), pruritus (&le;2%), skin photosensitivity (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased serum triglycerides (&le;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (&le;9%), abdominal pain (children &gt;4%), vomiting (&ge;4%), constipation (&le;4%), flatulence (children &le;4%), nausea (children &le;4%), xerostomia (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Leukopenia (&le;2%), thrombocytopenia (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Abnormal hepatic function tests (&le;4%), hepatitis (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction (&le;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Inflammation at injection site (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (&le;4%), myalgia (&le;4%), increased creatine phosphokinase (&le;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (children &gt;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (adults &le;2%; children &gt;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Ageusia, agranulocytosis, anaphylaxis (including anaphylactic shock), angioedema, bone fracture, <i>Clostridium difficile</i>-associated diarrhea, confusion, contact dermatitis, cutaneous lupus erythematous, decreased libido, diabetes mellitus, drowsiness, dysgeusia, ECG abnormality, eosinophilia, erythema multiforme, esophagitis, fatigue, gastric ulcer, gastrointestinal carcinoma, hallucination, hematuria, hepatic failure, hepatotoxicity (idiosyncratic) (Chalasani 2014), hyperbilirubinemia, hypertension, hypokinesia, hypomagnesemia, hyponatremia, impotence, increased appetite, increased serum alkaline phosphatase, interstitial nephritis, ischemic heart disease, jaundice, leukocytosis, malaise, neoplasm, nervousness, optic neuropathy (including anterior ischemic), pancreatitis, pancytopenia, paresthesia, pneumonia (Eom 2011), renal disease (chronic; Lazarus 2016), rhabdomyolysis, Stevens-Johnson syndrome, systemic lupus erythematosus, thrombosis, tinnitus, tongue discoloration, toxic epidermal necrolysis, tremor, visual disturbance, weakness, weight changes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206217\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity (eg, anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute interstitial nephritis, urticaria) to pantoprazole, other substituted benzimidazole proton pump inhibitors, or any component of the formulation; in combination with rilpivirine-containing products.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Concomitant use with rilpivirine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206199\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Carcinoma: Benign and malignant neoplasia has been observed in long-term (2-year) rodent studies; while not reported in humans, the relevance of these findings in regards to tumorigenicity in humans is not known.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; <i>Clostridium difficile</i>-associated diarrhea (CDAD): Use of proton pump inhibitors (PPIs) may increase risk of CDAD, especially in hospitalized patients; consider CDAD diagnosis in patients with persistent diarrhea that does not improve. Use the lowest dose and shortest duration of PPI therapy appropriate for the condition being treated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cutaneous and systemic lupus erythematosus: Has been reported as new onset or exacerbation of existing autoimmune disease; most cases were cutaneous lupus erythematosus (CLE), most commonly, subacute CLE (occurring within weeks to years after continuous therapy). Systemic lupus erythematosus (SLE) is less common (typically occurs within days to years after initiating treatment) and occurred primarily in young adults up to elderly patients. Discontinue therapy if signs or symptoms of CLE or SLE occur and refer to specialist for evaluation; most patients improve 4 to 12 weeks after discontinuation of pantoprazole.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fractures: Increased incidence of osteoporosis-related bone fractures of the hip, spine, or wrist may occur with proton pump inhibitor (PPI) therapy. Patients on high-dose or long-term therapy (&ge;1 year) should be monitored. Use the lowest effective dose for the shortest duration of time, use vitamin D and calcium supplementation, and follow appropriate guidelines to reduce risk of fractures in patients at risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI infection (eg, <i>Salmonella, Campylobacter</i>): Use of PPIs may increase risk of these infections.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Mild, transient transaminase elevations have been observed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypomagnesemia: Reported rarely, usually with prolonged PPI use of &ge;3 months (most cases &gt;1 year of therapy). May be symptomatic or asymptomatic; severe cases may cause tetany, seizures, and cardiac arrhythmias. Consider obtaining serum magnesium concentrations prior to beginning long-term therapy, especially if taking concomitant digoxin, diuretics, or other drugs known to cause hypomagnesemia; and periodically thereafter. Hypomagnesemia may be corrected by magnesium supplementation, although discontinuation of pantoprazole may be necessary; magnesium levels typically return to normal within 2 weeks of stopping.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion-related reactions: Thrombophlebitis and serious hypersensitivity reactions, including anaphylaxis, erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported with IV administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Interstitial nephritis: Acute interstitial nephritis has been observed in patients taking PPIs; may occur at any time during therapy and is generally due to an idiopathic hypersensitivity reaction. Discontinue if acute interstitial nephritis develops.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vitamin B<sub>12</sub> deficiency: Prolonged treatment (&ge;2 years) may lead to vitamin B<sub>12</sub> malabsorption and subsequent vitamin B<sub>12</sub> deficiency. The magnitude of the deficiency is dose-related and the association is stronger in females and those younger in age (&lt;30 years); prevalence is decreased after discontinuation of therapy (Lam 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastric malignancy: Relief of symptoms does not preclude the presence of a gastric malignancy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends either avoidance of both omeprazole (even when scheduled 12 hours apart) and esomeprazole or use of a PPI with comparatively less effect on the active metabolite of clopidogrel. Of the PPIs, pantoprazole has the lowest degree of CYP2C19 inhibition <i>in vitro</i> (Li 2004) and has been shown to have less effect on conversion of clopidogrel to its active metabolite compared to omeprazole (Angiolillo 2011). In contrast to these warnings, others have recommended the continued use of PPIs, regardless of the degree of inhibition, in patients with a history of GI bleeding or multiple risk factors for GI bleeding who are also receiving clopidogrel since no evidence has established clinically meaningful differences in outcome; however, a clinically significant interaction cannot be excluded in those who are poor metabolizers of clopidogrel (Abraham 2010, Levine 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Edetate sodium (EDTA): Some dosage forms may contain edetate sodium; use caution in patients who are at risk for zinc deficiency if other EDTA-containing solutions are coadministered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: <i>Helicobacter pylori</i> eradication: Short-term combination therapy (&le;7 days) has been associated with a higher incidence of treatment failure. The American College of Gastroenterology recommends 10 to 14 days of therapy (triple or quadruple) for eradication of <i>H. pylori</i> (Chey 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206277\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2C19 (major), CYP2D6 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> BCRP/ABCG2</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206204\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9474&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acalabrutinib: Proton Pump Inhibitors may decrease the serum concentration of Acalabrutinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamine: Proton Pump Inhibitors may increase the absorption of Amphetamine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atazanavir: Proton Pump Inhibitors may decrease the serum concentration of Atazanavir.  Management: See full drug interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Proton Pump Inhibitors may diminish the therapeutic effect of Bisphosphonate Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosutinib: Proton Pump Inhibitors may decrease the serum concentration of Bosutinib.  Management: Consider alternatives to proton pump inhibitors, such as antacids or H2 receptor antagonists.  Administer alternative agents more than 2 hours before or after bosutinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capecitabine: Proton Pump Inhibitors may diminish the therapeutic effect of Capecitabine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefditoren: Proton Pump Inhibitors may decrease the serum concentration of Cefditoren.  Management: If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefpodoxime: Proton Pump Inhibitors may decrease the serum concentration of Cefpodoxime. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefuroxime: Proton Pump Inhibitors may decrease the absorption of Cefuroxime. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clopidogrel: Pantoprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel.  Management: Due to the possible risk for impaired clopidogrel effectiveness, clinicians should carefully consider the need for proton pump inhibitor therapy in patients receiving clopidogrel.  Other acid-lowering therapies do not appear to share this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cysteamine (Systemic): Proton Pump Inhibitors may diminish the therapeutic effect of Cysteamine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Dabigatran Etexilate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP2C19 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP2C19 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: Proton Pump Inhibitors may decrease the serum concentration of Dabrafenib. Dabrafenib may decrease the serum concentration of Proton Pump Inhibitors.  Management: Seek alternatives to the proton pump inhibitor when possible.  If concomitant therapy cannot be avoided, monitor for diminished effects of both drugs.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: Proton Pump Inhibitors may decrease the serum concentration of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of the proton pump inhibitor if some acid-reducing therapy is needed.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Delavirdine: Proton Pump Inhibitors may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with proton pump inhibitors (PPIs) should be avoided in patients treated with delavirdine.  The clinical significance of short-term PPI therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexmethylphenidate: Proton Pump Inhibitors may increase the absorption of Dexmethylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dextroamphetamine: Proton Pump Inhibitors may increase the absorption of Dextroamphetamine. Specifically, the dextroamphetamine absorption rate from mixed amphetamine salt extended release (XR) capsules may be increased in the first hours after dosing. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP2C19 Substrates (High risk with Inducers). Conversely, concentrations of active metabolites may be increased for those drugs activated by CYP2C19. Management: Concurrent use of enzalutamide with CYP2C19 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP2C19 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erlotinib: Proton Pump Inhibitors may decrease the serum concentration of Erlotinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May increase the serum concentration of Proton Pump Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gefitinib: Proton Pump Inhibitors may decrease the serum concentration of Gefitinib.  Management: Avoid use of proton pump inhibitors (PPIs) with gefitinib when possible. If required, administer gefitinib 12 hours after administration of the PPI or 12 hours before the next dose of the PPI.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indinavir: Proton Pump Inhibitors may decrease the serum concentration of Indinavir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: Proton Pump Inhibitors may decrease the absorption of Iron Salts. <b> Exceptions: </b>Ferric Carboxymaltose; Ferric Citrate; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: Proton Pump Inhibitors may decrease the serum concentration of Itraconazole. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): Proton Pump Inhibitors may decrease the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Proton Pump Inhibitors. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ledipasvir: Proton Pump Inhibitors may decrease the serum concentration of Ledipasvir.  Management: PPI doses equivalent to omeprazole 20 mg or lower may be given with ledipasvir under fasted conditions. Administration with higher doses of PPIs, 2 hours after a PPI, or in combination with food and PPIs may reduce ledipasvir bioavailability.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of CYP2C19 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mesalamine: Proton Pump Inhibitors may diminish the therapeutic effect of Mesalamine. Proton pump inhibitor-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Consider avoiding concurrent administration of high-dose proton pump inhibitors (PPIs) with sustained-release mesalamine products.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Proton Pump Inhibitors may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: Proton Pump Inhibitors may increase the absorption of Methylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): Proton Pump Inhibitors may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be decreased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Proton Pump Inhibitors may decrease the serum concentration of Mycophenolate. Specifically, concentrations of the active mycophenolic acid may be reduced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nelfinavir: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Nelfinavir. Proton Pump Inhibitors may decrease the serum concentration of Nelfinavir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neratinib: Proton Pump Inhibitors may decrease the serum concentration of Neratinib. Specifically, proton pump inhibitors may reduce neratinib absorption. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nilotinib: Proton Pump Inhibitors may decrease the serum concentration of Nilotinib.  Management: Avoid this combination when possible since separation of doses is not likely to be an adequate method of minimizing the interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PAZOPanib: Proton Pump Inhibitors may decrease the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Posaconazole: Proton Pump Inhibitors may decrease the serum concentration of Posaconazole. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Raltegravir: Proton Pump Inhibitors may increase the serum concentration of Raltegravir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilpivirine: Proton Pump Inhibitors may decrease the serum concentration of Rilpivirine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Riociguat: Proton Pump Inhibitors may decrease the serum concentration of Riociguat. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Risedronate: Proton Pump Inhibitors may diminish the therapeutic effect of Risedronate. Proton Pump Inhibitors may increase the serum concentration of Risedronate. This applies specifically to use of delayed-release risedronate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saquinavir: Proton Pump Inhibitors may increase the serum concentration of Saquinavir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Secretin: Proton Pump Inhibitors may diminish the diagnostic effect of Secretin. Specifically, use of PPIs may cause a hyperresponse in gastrin secretion in response to secretin stimulation testing, falsely suggesting gastrinoma.  Management: Avoid concomitant use of proton pump inhibitors (PPIs) and secretin, and discontinue PPIs several weeks prior to secretin administration, with the duration of separation determined by the specific PPI. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May decrease the serum concentration of Proton Pump Inhibitors. These data are derived from studies with Ritonavir-boosted Tipranavir.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Velpatasvir: Proton Pump Inhibitors may decrease the serum concentration of Velpatasvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: May increase the serum concentration of Proton Pump Inhibitors. Proton Pump Inhibitors may increase the serum concentration of Voriconazole. Management: In patients receiving omeprazole 40 mg/day or greater, reduce omeprazole dose by half when initiating voriconazole.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24794079\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Prolonged treatment (&ge;2 years) may lead to malabsorption of dietary vitamin B<sub>12</sub> and subsequent vitamin B<sub>12</sub> deficiency (Lam, 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206207\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206220\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Most available studies have not shown an increased risk of major birth defects following maternal use of proton pump inhibitors during pregnancy (Diav-Citrin 2005; Erichsen 2012; Matok 2012; Pasternak 2010). When treating GERD in pregnancy, PPIs may be used when clinically indicated (Katz 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206221\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Pantoprazole is present in breast milk. The excretion of pantoprazole into breast milk was studied in a breastfeeding woman, 10 months postpartum. Following a single dose of pantoprazole 40 mg, maternal milk and serum samples were obtained over 24 hours. Peak concentrations appeared in both the plasma and milk 2 hours after the dose. Pantoprazole concentrations in breast milk were below the limits of detection during most of the study period. Based on this single dose study, the authors calculated the expected exposure to a breastfeeding infant to be 0.14% of the weight-adjusted maternal dose (Plante 2004). Due to the potential for serious adverse reactions in the breastfeeding infant, the manufacturer recommends a decision be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother; however, the acidic content of the breastfeeding infants' stomach may potentially inactivate any ingested pantoprazole (Plante 2004).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206222\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">IV: Due to EDTA in preparation, zinc supplementation may be needed in patients prone to zinc deficiency.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206209\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bone loss and fractures, CDAD, magnesium (baseline and periodically thereafter), and serum gastrin levels</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersecretory disorders: Acid output measurements, target level &lt;10 mEq/hour (&lt;5 mEq/hour if prior gastric acid-reducing surgery)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206198\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Proton pump inhibitor, suppresses gastric acid secretion by inhibiting the parietal cell H<sup>+</sup>/K<sup>+</sup> ATP pump</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206216\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Pediatric patients who have the poor metabolizer genotype of CYP2C19 (CYP2C19 *2/*2) exhibited greater than a 6-fold increase in AUC compared with pediatric extensive (CYP2C19 *1/*1) and intermediate (CYP2C19 *1/*x) metabolizers. Poor metabolizers exhibited approximately 10-fold lower apparent oral clearance compared with extensive metabolizers.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Acid secretion: Oral: 2.5 hours; IV: 15 to 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Maximum effect: IV: 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid, well absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Oral, IV: 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents (Kearns 2008): IV (2 to 16 years of age): 0.22 &plusmn; 0.14 L/kg; Oral (5 to 16 years of age): 0.24 &plusmn; 0.09 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 11 to 23.6 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 98%, primarily to albumin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Extensively hepatic; CYP2C19 (demethylation), CYP3A4; no evidence that metabolites have pharmacologic activity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: ~77%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates (PMA: 37 to 44 weeks): ~3 hours (Ward 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents (Kearns 2008): IV (2 to 16 years of age): 1.22 &plusmn; 0.68 hours; Oral (5 to 16 years of age): 1.27 &plusmn; 1.29 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 1 hour; increased to 3.5 to 10 hours with CYP2C19 deficiency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents (Kearns 2008): IV (2 to 16 years of age): 0.34 &plusmn; 0.12 hours; Oral (5 to 16 years of age): 2.54 &plusmn; 0.72 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Oral: 2.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (71% as metabolites); feces (18%); pantoprazole clearance increased with weight and age (Pettersen 2009)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206219\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (Protonix Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (1): $17.22</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Pantoprazole Sodium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (1): $8.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Protonix Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (1): $6.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Pantoprazole Sodium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (90): $368.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (90): $368.22</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Protonix Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (90): $1,549.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (90): $1,549.58</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206223\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acernix (PH);</li>\n      <li>Acipan (HR, SI);</li>\n      <li>Alapanzol (ES);</li>\n      <li>Alpanzole (SG);</li>\n      <li>Altana (PH);</li>\n      <li>Anagastra (ES);</li>\n      <li>Anxel (EE);</li>\n      <li>Apton (PT);</li>\n      <li>Axepron (PH);</li>\n      <li>Azatol (RO);</li>\n      <li>Azidex (AT);</li>\n      <li>Bio-Panto (VN);</li>\n      <li>Branzol (UY);</li>\n      <li>Ciproton (MX);</li>\n      <li>Conpanzole (MY);</li>\n      <li>Controloc (BG, CZ, EE, EG, HR, HU, IL, IR, JO, LT, LV, MT, MY, PK, PL, RO, RU, SE, SG, SI, SK, TH, ZA);</li>\n      <li>Eumac (IN);</li>\n      <li>Eupantol (FR);</li>\n      <li>Fozole (IN);</li>\n      <li>Gastenz (AU);</li>\n      <li>Gastroloc (TW);</li>\n      <li>Gastromax (AR);</li>\n      <li>Inipomp (FR);</li>\n      <li>Ipraalox (LU, LV);</li>\n      <li>Kaiji (CN);</li>\n      <li>Kontrolok (UA);</li>\n      <li>Kuppam (MX);</li>\n      <li>Leminter (MX);</li>\n      <li>Luoxu (CN);</li>\n      <li>Mefogin (VN);</li>\n      <li>Nixpan (BD);</li>\n      <li>Noacid (BG);</li>\n      <li>Nocid (PH);</li>\n      <li>Nolpaza (EE, LV, MY, SK);</li>\n      <li>Ottozol (ID);</li>\n      <li>Ozpan (AU);</li>\n      <li>Pandecta (ID);</li>\n      <li>Panfred (LK);</li>\n      <li>Panloc (ID);</li>\n      <li>Panoz (BD);</li>\n      <li>Panprax (CH);</li>\n      <li>Panrazol (HK);</li>\n      <li>Pantazol (PH);</li>\n      <li>Pantec (IN);</li>\n      <li>Pantecta (CR, DO, ES, GT, HN, IT, MT, NI, NL, PA, SV);</li>\n      <li>Panteon (KR);</li>\n      <li>Pantex (BD);</li>\n      <li>Pantin (SG);</li>\n      <li>Panto (TR);</li>\n      <li>Panto-Byk (LU);</li>\n      <li>Pantoavenir IV (IL);</li>\n      <li>Pantoc (PT);</li>\n      <li>Pantocar (LK, PH);</li>\n      <li>Pantocid (NZ, TH, ZA);</li>\n      <li>Pantodac (IN);</li>\n      <li>Pantodar (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Pantol (LV);</li>\n      <li>Pantoline (KR);</li>\n      <li>Pantoloc (AT, CN, DK, EG, ES, FR, HK, JO, KR, LT, PH, QA, SE, TW, TZ, VN);</li>\n      <li>Pantomax (QA);</li>\n      <li>Pantomed (KR);</li>\n      <li>Pantop (AR, PK, VE);</li>\n      <li>Pantopan (IN, IT);</li>\n      <li>Pantoprix (PH);</li>\n      <li>Pantoprol (TH);</li>\n      <li>Pantopump (ID);</li>\n      <li>Pantor (PH);</li>\n      <li>Pantostac (KR);</li>\n      <li>Pantostad (HK);</li>\n      <li>Pantover (QA);</li>\n      <li>Pantoz (LK);</li>\n      <li>Pantozol (AE, AT, BE, BH, CH, CY, DE, EG, ID, IQ, IR, JO, KW, LB, LU, LY, MT, MX, NL, OM, PH, QA, SA, SE, SY, YE);</li>\n      <li>Pantul (EE);</li>\n      <li>Panum (UA);</li>\n      <li>Panzol (BD, UA);</li>\n      <li>Panzole (MY, SG);</li>\n      <li>Panzomex (ID);</li>\n      <li>Panzor (FI);</li>\n      <li>Pauly (MX);</li>\n      <li>Pentowin (HK);</li>\n      <li>Peptazol (AR, MY, SG);</li>\n      <li>Peptazole (HK);</li>\n      <li>Pepticus (PY);</li>\n      <li>Pepzol (ID);</li>\n      <li>Peucetol (MX);</li>\n      <li>Pozola (TW);</li>\n      <li>Prompin (LK);</li>\n      <li>Protium (GB, IE);</li>\n      <li>Protocid (BD);</li>\n      <li>Proton (QA);</li>\n      <li>Protopan (PY);</li>\n      <li>Prozolan (MX);</li>\n      <li>Pulcet (BG);</li>\n      <li>Razon (LB);</li>\n      <li>Regad (MX);</li>\n      <li>Rifun 40 (DE);</li>\n      <li>Salpraz (AU);</li>\n      <li>Segregam (CO);</li>\n      <li>Somac (AU, CZ, FI, NO, NZ);</li>\n      <li>Sozol (AU, VN);</li>\n      <li>Stripole (TH);</li>\n      <li>Sunpraz (RU);</li>\n      <li>Tecta (CO, CR, DO, EC, GT, HN, MX, NI, PA, SV);</li>\n      <li>Tonval (PE);</li>\n      <li>Topazol (ID);</li>\n      <li>Toprazol (KR);</li>\n      <li>Toprazole (ET, MY);</li>\n      <li>Trupan (LK);</li>\n      <li>Ulcemex (CL, PY);</li>\n      <li>Ulcoreks (ET);</li>\n      <li>Ulprix (BG);</li>\n      <li>Unigastrozol (MX);</li>\n      <li>Vencid (MY);</li>\n      <li>Vomizole (ID);</li>\n      <li>Xotepic (PL);</li>\n      <li>Zolpra (MX);</li>\n      <li>Zoltum (CR, DO, EC, GT, HN, NI, PA, PE, SV);</li>\n      <li>Zurcal (AT, BR, CH, CL, CO, EC, MX, PE, PT);</li>\n      <li>Zurcale (BE);</li>\n      <li>Zurcamed (BE);</li>\n      <li>Zurcazol (GR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abraham NS, Hlatky MA, Antman EM, et al, &ldquo;ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents,&rdquo; <i>Circulation</i>, 2010, 122(24):2619-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/21060077/pubmed\" target=\"_blank\" id=\"21060077\">21060077</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Angiolillo DJ, Gibson CM, Cheng S, et al, &ldquo;Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo-Controlled, Crossover Comparison Studies,&rdquo; <i>Clin Pharmacol Ther</i>, 2011, 89(1):65-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/20844485/pubmed\" target=\"_blank\" id=\"20844485\">20844485</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baker R, Tsou VM, Tung J, et al. Clinical results from a randomized, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis. <i>Clin Pediatr (Phila).</i> 2010;49(9):852-865.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/20522615/pubmed\" target=\"_blank\" id=\"20522615\">20522615</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bardhan KD, Dillon J, Axon AT, et al, &ldquo;Triple Therapy for <i>Helicobacter pylori</i> Eradication: A Comparison of Pantoprazole Once Versus Twice Daily,&rdquo; <i>Aliment Pharmacol Ther</i>, 2000, 14(1):59-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/10632646/pubmed\" target=\"_blank\" id=\"10632646\">10632646</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20083829\"></a>Barkun AN, Bardou M, Kulpers EJ, et al; International Consensus Upper Gastrointestinal Bleeding Conference Group. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. <i>Ann Intern Med</i>. 2010;152(2):101-113.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/20083829/pubmed\" target=\"_blank\" id=\"20083829\">20083829</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bell AD, Roussin A, Cartier R, et al, &ldquo;The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines,&rdquo; <i>Can J Cardiol</i>, 2011, 27(Suppl A):1-59.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/21640290/pubmed\" target=\"_blank\" id=\"21640290\">21640290</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10975769\"></a>Bianchi Porro G, Lazzaroni M, Imbesi V, Montrone F, Santagada T. Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind, parallel-group study. <i>Dig Liver Dis</i>. 2000;32(3):201-208.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/10975769/pubmed\" target=\"_blank\" id=\"10975769\">10975769</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brunner G, Luna P, Hartmann M, et al, &ldquo;Optimizing the Intragastric pH as a Supportive Therapy in Upper GI Bleeding,&rdquo; <i>Yale J Biol Med</i>, 1996, 69(3):225-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/9165691/pubmed\" target=\"_blank\" id=\"9165691\">9165691</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/24935270/pubmed\" target=\"_blank\" id=\"24935270\">24935270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28071659\"></a>Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. <i>Am J Gastroenterol</i>. 2017;112(2):212-239. doi: 10.1038/ajg.2016.563.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/28071659/pubmed\" target=\"_blank\" id=\"28071659\">28071659</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chey WD, Wong BC, et al, &ldquo;American College of Gastroenterology Guideline on the Management of <i>Helicobacter pylori</i> Infection,&rdquo; <i>Am J Gastroent</i>, 2007, 102(8):1808-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/17608775/pubmed\" target=\"_blank\" id=\"17608775\">17608775</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cockayne SE, Glet RJ, Gawkrodger DJ, et al, &ldquo;Severe Erythrodermic Reactions to the Proton Pump Inhibitors Omeprazole and Lansoprazole,&rdquo; <i>Br J Dermatol</i>,1999, 141(1):173-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/10417548/pubmed\" target=\"_blank\" id=\"10417548\">10417548</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Jager CP, Wever PC, Gemen EF, et al, &ldquo;Proton Pump Inhibitor Therapy Predisposes to Community-Acquired <i>Streptococcus pneumoniae</i> Pneumonia,&rdquo; <i>Aliment Pharmacol Ther</i>, 2012, 36(10):941-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/23034135/pubmed\" target=\"_blank\" id=\"23034135\">23034135</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dettmer A, Vogt R, Sielaff F, et al, &ldquo;Pantoprazole 20 mg is Effective for Relief of Symptoms and Healing of Lesions in Mild Reflux Oesophagitis,&rdquo; <i>Aliment Pharmacol Ther</i>, 1998, 12(9): 865-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/9768529/pubmed\" target=\"_blank\" id=\"9768529\">9768529</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diav-Citrin O, Arnon J, Shechtman S, et al, &quot;The Safety of Proton Pump Inhibitors in Pregnancy: A Multicentre Prospective Controlled Study,&quot; <i>Aliment Pharmacol Ther</i>, 2005, 21(3):269-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/15691301/pubmed\" target=\"_blank\" id=\"15691301\">15691301</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. <i>CMAJ</i>. 2011;183(3):310-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/21173070/pubmed\" target=\"_blank\" id=\"21173070\">21173070</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Erichsen R, Mikkelsen E, Pedersen L, et al, &quot;Maternal Use of Proton Pump Inhibitors During Early Pregnancy and the Prevalence of Hypospadias in Male Offspring,&quot; <i>Am J Ther</i>, 2012.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/22314213/pubmed\" target=\"_blank\" id=\"22314213\">22314213</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Escourrou J, Deprez P, Saggioro A, et al, &ldquo;Maintenance Therapy With Pantoprazole 20 mg Prevents Relapse of Reflux Oesophagitis,&rdquo; <i>Aliment Pharmacol Ther</i>, 1999, 13(11):1481-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/10571605/pubmed\" target=\"_blank\" id=\"10571605\">10571605</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of <i>Helicobacter pylori</i> infection in adults. <i>Gastroenterology.</i> 2016;151(1):51-69.e14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/27102658/pubmed\" target=\"_blank\" id=\"27102658\">27102658</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20233195\"></a>Hsu YC, Perng CL, Yang TH, et al. A randomized controlled trial comparing two different dosages of infusional pantoprazole in peptic ulcer bleeding. <i>Br J Clin Pharmacol</i>. 2010;69(3):245-251.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/20233195/pubmed\" target=\"_blank\" id=\"20233195\">20233195</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17635283\"></a>Hung WK, Li VK, Chung CK, et al. Randomized trial comparing pantoprazole infusion, bolus and no treatment on gastric pH and recurrent bleeding in peptic ulcers. <i>ANZ J Surg</i>. 2007;77(8):677-681.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/17635283/pubmed\" target=\"_blank\" id=\"17635283\">17635283</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johnson CE, &ldquo;Stability of Pantoprazole in 0.9% Sodium Chloride Injection in Polypropylene Syringes,&rdquo; <i>Am J Health Syst Pharm</i>, 2005, 62(22):2410-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/16278334/pubmed\" target=\"_blank\" id=\"16278334\">16278334</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jung R and MacLaren R, &ldquo;Proton-Pump Inhibitors for Stress Ulcer Prophylaxis in Critically Ill Patients,&rdquo; <i>Ann Pharmacother</i>, 2002, 36(12):1929-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/12452757/pubmed\" target=\"_blank\" id=\"12452757\">12452757</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kahrilas PJ, Shaheen NJ, Vaezi MF, et al, &ldquo;American Gastroenterological Association Medical Position Statement on the Management of Gastroesophageal Reflux Disease,&rdquo; <i>Gastroenterology</i>, 2008, 135(4):1383-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/18789939/pubmed\" target=\"_blank\" id=\"18789939\">18789939</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Katz PO, Gerson LB, and Vela MF, &quot;Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease,&quot; <i>Am J Gastroenterol</i>, 2013, 108(3):308-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/23419381/pubmed\" target=\"_blank\" id=\"23419381\">23419381</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kearns GL, Blumer J, Schexnayder S, et al, &quot;Single-Dose Pharmacokinetics of Oral and Intravenous Pantoprazole in Children and Adolescents,&quot; <i>J Clin Pharmacol</i>, 2008, 48(11):1356-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/18664620/pubmed\" target=\"_blank\" id=\"18664620\">18664620</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22310222\"></a>Laine L, Jensen DM. Management of patients with ulcer bleeding. <i>Am J Gastroenterol</i>. 2012;107(3):345-360. doi: 10.1038/ajg.2011.480.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/22310222/pubmed\" target=\"_blank\" id=\"22310222\">22310222</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. <i>JAMA</i>. 2013;310(22):2435-2422.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/24327038/pubmed\" target=\"_blank\" id=\"24327038\">24327038</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19240698\"></a>Lanza FL, Chan FK, Quigley EM; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. <i>Am J Gastroenterol</i>. 2009;104(3):728-738. doi: 10.1038/ajg.2009.115.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/19240698/pubmed\" target=\"_blank\" id=\"19240698\">19240698</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23746903\"></a>Lau JY, Barkun A, Fan DM; Kuipers EJ, Yang YS, Chan FK. Challenges in the management of acute peptic ulcer bleeding. <i>Lancet</i>. 2013;381:2033-2043.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/23746903/pubmed\" target=\"_blank\" id=\"23746903\">23746903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lau JY, Leung WK, Wu JC, et al, &ldquo;Omeprazole Before Endoscopy in Patients With Gastrointestinal Bleeding,&rdquo; <i>N Engl J Med</i>, 2007, 356(16):1631-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/17442905/pubmed\" target=\"_blank\" id=\"17442905\">17442905</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lau JY, Sung JJ, Lee KK, et al, &ldquo;Effect of Intravenous Omeprazole on Recurrent Bleeding After Endoscopic Treatment of Bleeding Peptic Ulcers,&rdquo; <i>N Engl J Med</i>, 2000, 343(5):310-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/10922420/pubmed\" target=\"_blank\" id=\"10922420\">10922420</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. <i>JAMA Intern Med</i>. 2016:238-246.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo; <i>Circulation</i>, 2011, 124(23):e574-651.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/22064601/pubmed\" target=\"_blank\" id=\"22064601\">22064601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lew EA, Pisegna JR, Starr JA, et al, &ldquo;Intravenous Pantoprazole Rapidly Controls Gastric Acid Hypersecretion in Patients With Zollinger-Ellison Syndrome,&rdquo; <i>Gastroenterology</i>, 2000, 118(4):696-704.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/10734021/pubmed\" target=\"_blank\" id=\"10734021\">10734021</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lin HJ, Lo WC, Lee FY, et al, &ldquo;A Prospective Randomized Comparative Trial Showing That Omeprazole Prevents Rebleeding in Patients With Bleeding Peptic Ulcer After Successful Endoscopic Therapy,&rdquo; <i>Arch Intern Med</i>, 1998, 158(1):54-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/9437379/pubmed\" target=\"_blank\" id=\"9437379\">9437379</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li X-Q, Anderson TB, Ahlstrom M, et al, &ldquo;Comparison of Inhibitory Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole on Human Cytochrome P450 Activities,&rdquo; <i>Drug Metab Disp</i>, 2004, 32(8):821-7.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Madrazo-de la Garza A, Dibildox M, Vargas A, et al, &ldquo;Efficacy and Safety of Oral Pantoprazole 20 mg Given Once Daily for Reflux Esophagitis in Children,&rdquo; <i>J Pediatr Gastroenterol Nutr</i>, 2003, 36(2):261-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/12548064/pubmed\" target=\"_blank\" id=\"12548064\">12548064</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Matok I, Levy A, Wiznitzer A, et al, &quot;The Safety of Fetal Exposure to Proton-Pump Inhibitors During Pregnancy,&quot; <i>Dig Dis Sci</i>, 2012, 57(3):699-705.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/22038541/pubmed\" target=\"_blank\" id=\"22038541\">22038541</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moayyedi PM, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N. ACG and CAG clinical guideline: management of dyspepsia. <i>Am J Gastroenterol</i>. 2017;112(7):988-1013. doi: 10.1038/ajg.2017.154.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/28631728/pubmed\" target=\"_blank\" id=\"28631728\">28631728</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morgan D, &ldquo;Intravenous Proton-Pump Inhibitors in the Critical Care Setting,&rdquo; <i>Crit Care Med</i>, 2002, 30(6 Suppl):369-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/12072664/pubmed\" target=\"_blank\" id=\"12072664\">12072664</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Natsch S, Vinks MH, Voogt AK, et al, &ldquo;Anaphylactic Reactions to Proton-Pump Inhibitors,&rdquo; <i>Ann Pharmacother</i>, 2000, 34(4):474-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/10772433/pubmed\" target=\"_blank\" id=\"10772433\">10772433</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Panto IV (pantoprazole) [product monograph]. Oakville, Ontario, Canada: Takeda Canada Inc; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pantoloc (pantoprazole) [product monograph]. Oakville, Ontario, Canada: Takeda Canada Inc.; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Paoluzi P, Iacopini F, Crispino P, et al, &ldquo;2-Week Triple Therapy for <i>Helicobacter pylori</i> Infection is Better Than 1-Week in Clinical Practice: a Large Prospective Single-Center Randomized Study,&rdquo; <i>Helicobacter</i>, 2006, 11(6):562-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/17083378/pubmed\" target=\"_blank\" id=\"17083378\">17083378</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pasternak B and Hviid A, &quot;Use of Proton-Pump Inhibitors in Early Pregnancy and the Risk of Birth Defects,&quot; <i>N Engl J Med</i>, 2010, 363(22):2114-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/21105793/pubmed\" target=\"_blank\" id=\"21105793\">21105793</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perri F, Festa V, Clemente R, et al, &ldquo;Randomized Study of Two &ldquo;Rescue&rdquo; Therapies for <i>Helicobacter pylori</i>-infected Patients After Failure of Standard Triple Therapies,&rdquo; <i>Am J Gastroenterol</i>, 2001, 96(1):58-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/11197288/pubmed\" target=\"_blank\" id=\"11197288\">11197288</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pettersen G, Mouksassi MS, Theoret Y, et al. Population pharmacokinetics of intravenous pantoprazole in paediatric intensive care patients. <i>Br J Clin Pharmacol</i>. 2009;67(2):216-227.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/19173681/pubmed\" target=\"_blank\" id=\"19173681\">19173681</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Plante L, Ferron GM, Unruh M, et al, &quot;Excretion of Pantoprazole in Human Breast,&quot; <i>J Reprod Med</i>, 2004, 49(10):825-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/15568407/pubmed\" target=\"_blank\" id=\"15568407\">15568407</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Poole P, &ldquo;Pantoprazole,&rdquo; <i>Am J Health-Syst Pharm</i>, 2001, 58:999-1008.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/11402494/pubmed\" target=\"_blank\" id=\"11402494\">11402494</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Protonix Oral (pantoprazole) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Protonix I.V. (pantoprazole) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16817839\"></a>Regula J, Butruk E, Dekkers CP, et al. Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole. <i>Am J Gastroenterol</i>. 2006;101(8):1747-1755.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/16817839/pubmed\" target=\"_blank\" id=\"16817839\">16817839</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016.<i> Intensive Care Med.</i> 2017;43(3):304-377. doi: 10.1007/s00134-017-4683-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/28101605/pubmed\" target=\"_blank\" id=\"28101605\">28101605</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25201154\"></a>Sachar H, Vaidya K, Laine L. Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers: a systematic review and meta-analysis. <i>JAMA Intern Med</i>. 2014;174(11):1755-1762.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/25201154/pubmed\" target=\"_blank\" id=\"25201154\">25201154</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"1846964\"></a>Somberg L, Morris J, Fantus R, et al, &ldquo;Intermittent Intravenous Pantoprazole and Continuous Cimetidine Infusion: Effect on Gastric pH Control in Critically Ill Patients at Risk of Developing Stress-Related Mucosal Disease,&rdquo; <i>J Trauma</i>, 2008, 64(5):1202-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/1846964/pubmed\" target=\"_blank\" id=\"1846964\">1846964</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sung JJ, Barkun A, Kuipers EJ, et al, &ldquo;Intravenous Esomeprazole for Prevention of Recurrent Peptic Ulcer Bleeding: A Randomized Trial,&rdquo; <i>Ann Intern Med</i>, 2009, 150(7):455-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/19221370/pubmed\" target=\"_blank\" id=\"19221370\">19221370</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Talley NJ and Vakil N, &ldquo;Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the Management of Dyspepsia,&rdquo; <i>Am J Gastroenterol</i>, 2005, 100(10):2324-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/16181387/pubmed\" target=\"_blank\" id=\"16181387\">16181387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tecta (pantoprazole) [product monograph]. Oakville, Ontario, Canada: Takeda Canada Inc; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tolia V, Bishop PR, Tsou VM, et al, &ldquo;Multicenter, Randomized, Double-Blind Study Comparing 10, 20 and 40 mg Pantoprazole in Children (5-11 Years) With Symptomatic Gastroesophageal Reflux Disease,&rdquo; <i>J Pediatr Gastroenterol Nutr</i>, 2006, 42(4):384-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/16641576/pubmed\" target=\"_blank\" id=\"16641576\">16641576</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tsou VM, Baker R, Book L, et al, &ldquo;Multicenter, Randomized, Double-Blind Study Comparing 20 and 40 mg of Pantoprazole for Symptom Relief in Adolescents (12 to 16 Years of Age) With Gastroesophageal Refulx Disease (GERD),&rdquo; <i>Clin Pediatr</i>, 2006, 45(8):741-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/16968960/pubmed\" target=\"_blank\" id=\"16968960\">16968960</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vcev A, Stimac D, Ivandic A, et al, &ldquo;Pantoprazole, Amoxycillin, and Either Azithromycin or Clarithromycin for Eradication of <i>Helicobacter pylori</i> in Duodenal Ulcer,&rdquo; <i>Aliment Pharmacol Ther</i>, 2000, 14(1):69-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/10632647/pubmed\" target=\"_blank\" id=\"10632647\">10632647</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ward RM, Tammara B, Sullivan SE, et al. Single-dose, multiple-dose, and population pharmacokinetics of pantroprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD). <i>Eur J Clin Pharmacol</i>. 2010;66:555-561.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/20306184/pubmed\" target=\"_blank\" id=\"20306184\">20306184</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wolfe MM and Sachs G, &ldquo;Acid Suppression: Optimizing Therapy for Gastroduodenal Ulcer Healing, Gastroesophageal Reflux Disease, and Stress-Related Erosive Syndrome,&rdquo; <i>Gastroenterology</i>, 2000,118(2 Suppl 1):9-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/10868896/pubmed\" target=\"_blank\" id=\"10868896\">10868896</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22550833\"></a>Yamada S,Wongwanakul P. Randomized controlled trial of high dose bolus versus continuous intravenous infusion pantoprazole as an adjunct therapy to therapeutic endoscopy in massive bleeding peptic ulcer. <i>J Med Assoc Thai</i>. 2012;95(3):349-357.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/22550833/pubmed\" target=\"_blank\" id=\"22550833\">22550833</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Y&uuml;ksel I, Ataseven H, K&ouml;kl&uuml; S, et al. Intermittent versus continuous pantoprazole infusion in peptic ulcer bleeding: a prospective randomized study. <i>Digestion</i>. 2008;78(1):39-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/18824852/pubmed\" target=\"_blank\" id=\"18824852\">18824852</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16677158\"></a>Zargar SA, Javid G, Khan BA, et al. Pantoprazole infusion as adjuvant therapy to endoscopic treatment in patients with peptic ulcer bleeding: prospective randomized controlled trial. <i>J Gastroenterol Hepatol</i>. 2006;21(4):716-721.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-drug-information/abstract-text/16677158/pubmed\" target=\"_blank\" id=\"16677158\">16677158</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9474 Version 267.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50836901\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F206239\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F206240\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F206284\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F206244\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F5707304\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F206245\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F206246\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F206247\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F206211\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F206195\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F5950137\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F15386979\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F206213\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Adult\" href=\"#F14473039\" class=\"outlineLink\">Usual Infusion Concentrations: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F206212\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25470196\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F206294\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F206202\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F206217\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F206199\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F206277\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F206204\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F24794079\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F206207\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F206220\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F206221\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F206222\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F206209\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F206198\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F206216\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F206219\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F206223\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9474|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pantoprazole-patient-drug-information\" class=\"drug drug_patient\">Pantoprazole: Patient drug information</a></li><li><a href=\"topic.htm?path=pantoprazole-pediatric-drug-information\" class=\"drug drug_pediatric\">Pantoprazole: Pediatric drug information</a></li></ul></div></div>","javascript":null}